Unicycive Therapeutics, Inc. 8-K

What Happened Unicycive Therapeutics, Inc. (UNCY) filed a Form 8‑K on July 2, 2026 (Item 8.01) announcing that its ending cash balance was approximately $61.4 million as of June 30, 2026. The company says these are preliminary results for the quarter ended June 30, 2026 and were prepared by management.

Key Details

• Ending cash balance: approximately $61.4 million as of June 30, 2026.
• Period covered: preliminary results for the second quarter ended June 30, 2026.
• Assurance: the preliminary figures have not been audited, reviewed, or compiled by the company’s independent registered public accounting firm or any other independent accountants.
• Filing: reported on Form 8‑K under Item 8.01 (Other Events).

Why It Matters A company’s cash balance is a direct indicator of short-term liquidity and ability to fund operations, clinical programs, or other activities. Because these numbers are preliminary and unaudited, investors should treat them as estimates and look for the company’s upcoming quarterly filings (e.g., Form 10‑Q) for reviewed/audited financial statements and more complete context on revenue, expenses and cash runway.